explain all of the interindividual and interethnic differences in warfarin dose requirements. Besides these factors, it is well established that the variability of warfarin dosage is largely genetically determined. 1, 4 Genetic variations in the cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) genes are significantly associated with warfarin dose adjustment, because products of these genes play fundamental roles in the pharmacokinetics and pharmacodynamics of warfarin, respectively. 1, 3, 5, 6 Warfarin is administered as racemic mixture of the R and S enantiomer of the drug. 7 S warfarin, the more active enantiomer of the drug, is metabolized almost exclusively to 7-hydroxywarfarin by a highly polymorphic hepatic enzyme, CYP2C9. 8 To date, at least 8 single nucleotide polymorphisms (SNPs) in CYP2C9 have been found to be strongly associated with decreased enzymatic activity. 9 The most commonly reported variants, CYP2C9*2 (rs 1799853, c 430 C/T, p Arg144Cys) in exon 3 and CYP2C9*3 (rs 1057910, c 1075 A/C, p Ile359Leu) in exon 7 are responsible for a reduction in warfarin metabolism and are related with reduction in CYP2C9 enzyme activity to approximately 12%-70% and 5% of wild type CYP2C9 activity, respectively. 10, 11 The plasma levels of warfarin quickly rise to supratherapeutic level in carriers of the CYP2C9*2 and/or *3 allelic variants, and therefore they are associated with a lower warfarin dose requirement accompanied by a greater tendency to experience bleeding complications during warfarin therapy. 12 The vitamin K-dependent carboxylase catalyzes the oxygenation of vitamin K hydroquinone in parallel with the posttranslational carboxylation of specific glutamate side chains in vitamin K-dependent clotting factors II, VII, IX, and X, with resulting formation of γ-carboxyglutamate. 13, 14 During γ-carboxylation, the vitamin K hydroquinone is oxidized to vitamin K 2, 3-epoxide, and continued supply of vitamin K hydroquinone is provided by recycling of the vitamin K 2, 3-epoxide by VKORC1, a key pharmacological target of warfarin. 14, 15 Warfarin exerts its anticoagulant action by inhibiting of VKORC1 activity and preventing of vitamin K hydroquinone recycling. 13 Available evidence suggests that VKORC1 (rs 9926231, c -1639G/A) polymorphism is significantly associated to warfarin sensitivity and reduced dose requirements, because this polymorphism leads to decreased expression of VKORC1. 6, 16 To the authors' knowledge, the prevalence of CYP2C9*2 (430 C/T), *3 (1075 A/C) and VKORC1 (-1639G/A) polymorphisms among patients with cardiac valve replacement treated with warfarin has not been reported from northwest Iran. Accordingly, the objective of the current study was to determine the frequencies of CYP2C9*2, CYP2C9*3 and VKORC1 -1639G/A polymorphisms in patients from northwest Iran with history of heart valve replacement surgery, and to predict the possible effect of these variants and clinical factors on required warfarin dose. The genotypic and allelic distributions of CYP2C9 and VKORC1 polymorphisms have also been compared with the data from other populations.
Materials and Methods

Subjects and Clinical Data
The investigation was conducted on 100 unrelated patients (49 men and 51 women), who underwent cardiac valve surgery at the Department of Cardiovascular Surgery, Shahid Madani Hospital, Tabriz, Iran, during 2013-2015. The mean age of the men and women was 47.74 ± 2.08 years (range 22 to 75) and 51.40 ± 2.69 (range 15 to 89), respectively. A structured interview form was used at the time of enrollment to obtain demographic data (age, gender, ethnicity, weight, and height), detailed medical lifestyle (smoking history and dietary vitamin K intake), indication for therapy, concurrent medication, and comorbid conditions. The clinical and demographic characteristics of the studied patients are summarized in Table 1 . The patients with serious complications, including hepatic dysfunction, liver cirrhosis, renal insufficiency, coagulation disorders, thyroid disease, and cancer, and those receiving concurrent treatment interacting with warfarin were excluded from the study. After the cardiac valve replacement surgery, patients were therapeutically anticoagulated by warfarin. Initial warfarin doses were empirically determined by the physicians, who were unaware of the CYP2C9 and VKORC1 genotypes, and all patients had a target INR of 2-3. The present study was approved by the Ethics and Human Rights Committee of Tabriz University of Medical Sciences, and written informed consent in accordance with the Declaration of Helsinki was obtained from all subjects after the purpose of study was explained.
DOI: 10.1093/labmed/lmx072 DNA Extraction and CYP2C9 (CYP2C9*1, *2, *3) and VKORC1 (-1639G/A) Genotyping
Whole venous blood (5 mL) was taken from eligible patients and leukocyte genomic DNA was extracted from the blood specimen using the salting-out method as previously described by Miller et al. 17 The PCR-RFLP procedure was used for genotyping the CYP2C9*2 (430 C/T), CYP2C9*3 (1075 A/C) and VKORC1 (-1639G/A) polymorphisms. The PCR solutions contained 100 ng genomic DNA, 1X PCR buffer, 10 pmol of each specific primer (the forward primer 5'-GTATTTTGGCCTGAAACCCATA-3' and the reverse primer 5'-GGCCTTGGTTTTTCTCAACTC-3' for CYP2C9*2, the forward primer 5'-ATAATAATATGCACGAGGTCCAGAGATGC-3' and the reverse primer 5'-GATACTATGAATTTGGGACTTC-3' for CYP2C9*3, and the forward primer 5'-GCCAGCAGGAGAGGGAAATA-3' and the reverse primer 5'-AGTTTGGACTACAGGTGCCT-3' for VKORC1 -1639G/A), 10 nmol of each deoxyribonucleotide triphosphates, 1.5 mmol MgCl 2 and 1 U Taq polymerase in a final volume of 25 μL. Initial denaturation at 94°C for 5 min was followed by 35 cycles of denaturation at 95°C for 50 s, annealing at temperatures (60°C for CYP2C9*2 and CYP2C9*3, 59°C for VKORC1) for 40 s, extension at 72°C for 40 s, and final extension was performed at 72 °C for 5 min. The PCR products were separated on 2% agarose gel and visualized with ethidium bromide staining. The amplified PCR products were digested by restriction enzymes, and the digested fragments were separated on 3% agarose gel and visualized with ethidium bromide staining. The CYP2C9 430 T, CYP2C9 1075 C and -1639A alleles were characterized by the presence of the specific fragments. The resulting 454 bp PCR product (for CYP2C9*2) was digested overnight with the restriction enzyme Ava II. As shown in Figure 1A and 1B, the CYP2C9*1 and CYP2C9*3 genotypes were cut into fragments of 397 bp and 57 bp. The CYP2C9*2 genotype did not digest with Ava II. The 141 bp PCR product (for CYP2C9*3) was digested overnight with the restriction enzyme NsiI ( Figure 1B ). The CYP2C9*1 and CYP2C9*2 genotypes were cut into fragments of 110 bp and 31 bp ( Figure 1A ). The CYP2C9*3 genotype did not digest with NsiI. As shown in Figure 1C , the VKORC1 -1639G allele was cut into two fragments of 168 bp and 122 bp with the restriction enzyme Hpa II, whereas the VKORC1 -1639A allele remained uncut (290 bp).
Statistical Analysis
All statistical analyses were conducted using SPSS software version 16.0 (Chicago, IL) and all continuous variables were expressed as mean ± standard deviation (SD). We used the χ 2 test to evaluate the deviations of allelic frequencies for CYP2C9*2 (430C/T), *3 (1075A/C) and VKORC1 (-1639G/A) polymorphisms from Hardy-Weinberg equilibrium (HWE). The difference in genotype distributions of each polymorphism and frequencies of heterozygous, homozygous and mutated alleles among the men and women was evaluated using Pearson's χ 2 test. Univariate regression analysis was used to evaluate the influence of the independent variables (demographics, clinical and genetic factors) on required warfarin dose. P values less than .05 were statistically considered as significant.
Results
We found that the genotypic distributions for CYP2C9*2 (430 C/T) and VKORC1 (-1639G/A) polymorphisms were in accordance with the HWE (P > .05), while the distribution for CYP2C9*3 (1075 A/C) polymorphism was not in accordance with the HWE (P < .05). The genotypes and allele frequencies of the CYP2C9*2 (430C/T), *3 (1075A/C) and VKORC1 (-1639G/A) polymorphisms in all patients treated with warfarin after cardiac valve replacement are displayed in Table 2 . The prevalence of CYP2C9*2 variant allele was 10.5% and the distribution of heterozygous genotypes (*1/*2 and *2/*3) was 4% and 17%, respectively (Table 2) . Surprisingly, we failed to detect *2/*2 genotype in all the studied participants ( Table 2 ). The CYP2C9*3 variant allele was found in 39% of patients and the distribution of the genotypes was 23% for wild-type (*1/*1), 68% for heterozygous (*1/*3 and *2/*3), and 5% for mutant homozygous (*3/*3) ( Table 2 ). Our findings revealed that the frequency of VKORC1 -1639A mutant allele was 48%, and the prevalence of GG, GA, and AA genotypes was 23%, 58%, and 19%, respectively ( Table 2) . When the frequency of CYP2C9*2 (430C/T), *3 (1075A/C) and VKORC1 (-1639G/A) polymorphisms were compared between the men and women, we observed no significant difference in the prevalence of these polymorphisms (P > .05) ( Table 2) . Regarding the prevalence of CYP2C9 *2, *3 and VKORC1 -1639A alleles, we detected no statistical differences between men and women (P > .05). However, the frequencies of CYP2C9 *3 and VKORC1 -1639A alleles were higher in men compared with women ( Table 2) .
We found that patients with CYP2C9 *1 and VKORC1 -1639G alleles required the highest dosages of warfarin during initiation and long-time treatment, while the carriers of CYP2C9 variant *2 and *3 alleles and VKORC1 -1639A required less warfarin ( Table 3 and Figure 2 ). Therefore, detection of CYP2C9*2 (430C/T), *3 (1075A/C) and VKORC1 (-1639G/A) polymorphisms, raises the accuracy of warfarin dose prediction ( Table 3 and Figure 2 ). According to CYP2C9 genotypes, we divided patients into 3 groups including *1/*1 (extensive metabolizer [EM]), *1/*2 or *1/*3 (intermediate metabolizer [IM] ) and *2/*2, *2/*3, or *3/*3 (poor metabolizer [PM]), and then calculated the frequencies of combined genotype for CYP2C9 and VKORC1 polymorphism based on warfarin metabolism rate ( Table 4) . Our results showed that the frequency of metabolic phenotypes (EM, IM, and PM) was 23%, 55% and 22%, respectively ( Table 4) .
Univariate regression analysis revealed that the age, as a nongenetic factor, significantly influenced the daily warfarin dose requirement (P < .05) ( Table 5) . Based on the data in Table 5 we observed other nongenetic factors, including sex, weight, height and BMI, did not significantly influence the daily maintenance dose of warfarin in the study patients ( Table 5) . Our data also revealed that CYP2C9 *2 allele was significantly associated with warfarin dose requirements (P = .008) ( Table 5 ).
CYP2C9*1 allele, wild-type allele, is associated with normal enzyme activity; CYP2C9*2 allele, at nucleotide position 403 on the gene, a C was exchanged by a T; CYP2C9*3 allele, at nucleotide position 1075 on the gene, an A was exchanged by a C c At nucleotide position -1639 on the gene promoter a G was exchanged by an A
Discussion
Undoubtedly, the clinical application of pharmacogenomic/ pharmacogenetic findings prior to warfarin administration can help us to predict a better starting dose for individual patients and potentially shorten the period required to achieve a stable warfarin dose. In recent years, many investigations have been conducted to identify genetic factors that may be associated with therapeutic dose of warfarin. [10] [11] [12] [13] [14] [15] [16] It has been demonstrated that polymorphism in the genes for CYP2C9 and VKORC1 affect the pharmacokinetics and pharmacodynamics of warfarin. 6, 12, 16 We investigated the prevalence of CYP2C9*2, *3 and VKORC1 -1639G/A polymorphisms in patients from northwest Iran with history of cardiac valve replacement surgery. Our results revealed that *1/*3 was the most common genotype for CYP2C9 polymorphism (51%), followed by *1/*1 (23%), *2/*3 (17%), *3/*3 (5%), and *1/*2 (4%) in our population (Tables 2 and 6 ). However, in most studies regarding the genotypic distribution of CYP2C9, *1/*1 was reported as a most common genotype. Japanese (95.8%), 13 25 and Turkish (60%), 26 populations have the highest prevalence of CYP2C9 *1/*1 genotype ( Table 6 ). The *1/*3 genotype was the most prevalent CYP2C9 genotype in our studied population (51%), while the Japanese (4.2%), 13 Norwegian (6.7%), 20 American (6.1%) 18 and Malaysian (9.9%), 27 populations show very low frequency ( Table 6 ). Namazi et al revealed that CYP2C9 *2/*2 genotype was the most prevalent genotype in the Iranian population 28 ( Table 6 ).
They reported this data from Shiraz, Iran; the population they had studied was ethnically different from the northwest Iranian population, the Azari population. Moreover, in accordance with the findings of several previous studies 13, 19, 29 (Table 6) , we observed no CYP2C9 *2/*2 genotype among all the studied participants. Ethnic differences in allelic frequencies of CYP2C9*2, *3 variants were observed when the prevalence of these variants were compared between our findings and data from other populations. In contrast to our results, in the Indian (0.9%), 19 American (3.38%), 18 Norwegian (4.76%), 20 Iranian (5.5%), 28 British (6.19%) 24 and Malaysian (6.63%) 27 populations, the frequency of CYP2C9*3 allele was low. However, Yoshizawa et al showed that CYP2C9*3 allele is more common (61.49%) among the Japanese population. 13 The prevalence of CYP2C9*3 allele in was 10.5% in our population (Tables  2 and 6 ). Several studies show an almost similar pattern in this case. [20] [21] [22] [23] [24] [25] [26] For VKORC1, we found that the prevalence of the (-1639AA) genotype was 19% in our population, which is relatively similar to the studies in Lithuania (14.8%), 1 Norway (15.2%), 20 Sweden (15%), 23 the UK (14.5%), 24 France (20.1%), 25 and Brazil (15%) 30 (Table 6 ). However, the VKORC1 -1639AA genotype is widely distributed in the Japanese (89.10%) 13 and Chinese (83.70%) 31 populations. Moreover, in the Japanese and Chinese populations, (Table 6 ). In our findings, wild-type allele for VKORC1 -1639G/A polymorphism was reported as 52%, less than the frequency reported in the Lithuanian, American, Swedish, and Brazilian populations. 1, 18, 23, 30 These data suggest that the genotypic and allelic distribution of CYP2C9*2, *3 and VKORC1 -1639G/A polymorphisms varies considerably in different populations. A detailed justification for the discrepancies among these findings is not currently evident. These conflicting results may be partly explained by differences in ethnicity and number of studied subjects.
Our findings showed that individuals possessing combined VKORC1 and CYP2C9 genotypes (GG / *3/*3, GA / *2/*3, GA / *3/*3, AA/ *1/*3, AA / *2/*3 and AA / *3/*3) depicted lowest warfarin dose requirements (0.5-2.0 mg/day) ( Table 3 ). This data is consistent with the previous studies showing reduction in enzyme activity due to presence of *2 and *3 alleles and causing significantly lower dose of warfarin in comparison to *1 allele. 10, 11 The association between CYP2C9 polymorphisms and daily warfarin dose has been previously demonstrated. 5 The significant differences in mean dose requirements between each of the variant alleles compared with the wild type reported by Sconce et al. 5 The median dose for homozygotes of wild type allele (*1/*1) and VKORC1 -1639A individuals was approximately 3-4 mg/day. Sconce et al reported that carriers of the VKORC1 -1639AA genotype require a significantly lower daily dose of warfarin than those carrying the GA or the GG genotypes. 5 Low dose requirements in these individuals may be partly explained by presence of VKORC1 -1639A
allele. However, it seems that other genetic and nongenetic factors responsible for causing low dose requirements in Univariate regression analysis was performed to investigate clinical and genetic factors associated with the inter-individual variability in daily warfarin dose. Our results suggest that only CYP2C9 *2 allele is a genetic factor influencing warfarin dose requirement in our studied population (P = .008) ( Table 5 ). In addition to the genetic factors, we investigated other factors including age, sex, weight, height, BMI. In accordance with the findings of previous study in Japanese population, 13 we identified that age was associated with the variability observed in the daily warfarin dose ( Table 5 ).
In conclusion, our results confirmed that such age and presence of CYP2C9 *2 allele significantly affect the daily dosage of warfarin during initiation of warfarin therapy after cardiac valve replacement surgery. We believe this data can become the baseline for intervention in reducing the side effect of warfarin. LM
